02-LUN-65 Phase 2 Open Label Study of MAC-321 Administered Intravenously as a Single Agent for the Treatment of Non Small Cell Lung Cancer Refractory to Platinum Based Therapy

Grants and Contracts Details

StatusFinished
Effective start/end date5/23/035/31/05

Funding

  • Wyeth Research: $25,780.00